Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVT801 in Advanced Solid Tumors
NCT05114668Phase 1Completed
- Sponsor
- Kazia Therapeutics
- Start
- Nov 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EVT801 in solid tumor, renal cell carcinoma (RCC) and soft tissue sarcoma (STS) (2 arms), sponsored by Kazia Therapeutics. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 24 months and Adverse Event Safety Information at 36 months. Started Nov 2021; status: completed.
02
Drugs
EVT801
03
Conditions
solid tumorrenal cell carcinoma (RCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05114668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114668.